Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 316069, 9 pages
Research Article

Genetic Immunization with CDR3-Based Fusion Vaccine Confers Protection and Long-Term Tumor-Free Survival in a Mouse Model of Lymphoma

1Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy
2CIR, Section of Molecular Medicine and Biotechnology, University “Campus Bio-Medico”, Via Álvaro del Portillo 21, 00128 Rome, Italy
3Bio-Ker, Scientific Park “Polaris”, Località Piscinamanna, 09010 Pula (Cagliari), Italy

Received 9 November 2009; Accepted 4 February 2010

Academic Editor: Daila S. Gridley

Copyright © 2010 Sandra Iurescia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the V H C D R 3 1 0 9 1 1 6 epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.